Natural Killer and CD8 T Cells Contribute to Protection by Formalin Inactivated Respiratory Syncytial Virus Vaccination under a CD4-Deficient Condition

키워드

참고문헌 (45)

1. Kim HW, "Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine", Am J Epidemiol, 89, pp.422~434 (1969)
2. Peebles RS Jr, "Pathogenesis of respiratory syncytial virus infection in the murine model", Proc Am Thorac Soc, 2, pp.110~115 (2005)
3. van Drunen Littel, "Pathogenesis of respiratory syncytial virus", Curr Opin Virol, 2, pp.300~305 (2012)
4. Openshaw PJ, "Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G", Int Immunol, 4, pp.493~500 (1992)
5. Castilow EM, "Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination", Future Virol, 3, pp.445~454 (2008)
6. Murphy BR, "Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus(RSV)or purified F glycoprotein and challenged with RSV 3-6 months after immunization", Vaccine, 8, pp.497~502 (1990)
7. Connors M, "Resistance to respiratory syncytial virus(RSV)challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein(Vac-M2)is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies", J Virol, 66, pp.1277~1281 (1992)
8. 권영만, "Respiratory Syncytial Virus Fusion Protein-encoding DNA Vaccine Is Less Effective in Conferring Protection against Inflammatory Disease than a Virus-like Particle Platform", Immune Network, 19(3), pp.1~13 (2019), 대한면역학회
9. Domachowske JB, "Respiratory syncytial virus infection : immune response, immunopathogenesis, and treatment", Clin Microbiol Rev, 12, pp.298~309 (1999)
10. Connors M, "Pulmonary histopathology induced by respiratory syncytial virus(RSV)challenge of formalin-inactivated RSVimmunized BALB", c mice is abrogated by depletion of CD4+ T cells, 1992, pp.66, 7444~7451
11. Hwang HS, "Virus-like particle vaccine primes immune responses preventing inactivated-virus vaccine-enhanced disease against respiratory syncytial virus", Virology, 511, pp.142~151 (2017)
12. Ko EJ, "Virus-like nanoparticle and DNA vaccination confers protection against respiratory syncytial virus by modulating innate and adaptive immune cells", Nanomedicine(Lond), 11, pp.99~108 (2015)
13. Hwang HS, "Coimmunization with virus-like particle and DNA vaccines induces protection against respiratory syncytial virus infection and bronchiolitis", Antiviral Res, 110, pp.115~123 (2014)
14. Graham BS, "Respiratory syncytial virus infection in antimu-treated mice", J Virol, 65, pp.4936~4942 (1991)
15. Graham BS, "Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice", J Clin Invest, 88, pp.1026~1033 (1991)
16. Polack FP, "The future of respiratory syncytial virus vaccine development", Pediatr Infect Dis J, 23, pp.S65~ (2004)
17. Prince GA, "Respiratory syncytial virus infection in inbred mice", Infect Immun, 26, pp.764~766 (1979)
18. Altamirano-Lagos MJ, "Current animal models for understanding the pathology caused by the respiratory syncytial virus", Front Microbiol, 10, pp.873~ (2019)
19. Quan FS, "Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice", J Infect Dis, 204, pp.987~995 (2011)
20. Lee Y, "Soluble F proteins exacerbate pulmonary histopathology after vaccination upon respiratory syncytial virus challenge but not when presented on virus-like particles", Hum Vaccin Immunother, 13, pp.2594~2605 (2017)
21. Brazolot Millan CL, "CpG DNA can induce strong Th1humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice", Proc Natl Acad Sci U S A, 95, pp.15553~15558 (1998)
22. Visciano ML, "Effects of adjuvants on IgG subclasses elicited by virus-like particles", J Transl Med, 10, pp.4~ (2012)
23. Everard ML, "Analysis of cells obtained by bronchial lavage of infants with respiratory syncytial virus infection", Arch Dis Child, 71, pp.428~432 (1994)
24. Christiaansen AF, "The CD4 T cell response to respiratory syncytial virus infection", Immunol Res, 59, pp.109~117 (2014)
25. Knudson CJ, "RSV vaccine-enhanced disease is orchestrated by the combined actions of distinct CD4 T cell subsets", PLoS Pathog, 11, pp.e1004757~ (2015)
26. Kim KH, "Alum adjuvant enhances protection against respiratory syncytial virus but exacerbates pulmonary inflammation by modulating multiple innate and adaptive immune cells", PLoS One, 10, pp.e0139916~ (2015)
27. Moghaddam A, "A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines", Nat Med, 12, pp.905~907 (2006)
28. Boelen A, "Both immunisation with a formalin-inactivated respiratory syncytial virus(RSV)vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice", Vaccine, 19, pp.982~991 (2000)
29. Waris ME, "Respiratory synctial virus infection in BALB", c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern, 1996, pp.70, 2852~2860
30. Prince GA, "Monophosphoryl lipid A adjuvant reverses a principal histologic parameter of formalin-inactivated respiratory syncytial virus vaccine-induced disease", Vaccine, 19, pp.2048~2054 (2001)
31. Kamphuis T, "Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice", PLoS One, 7, pp.e36812~ (2012)
32. Johnson TR, "Respiratory syncytial virus(RSV)G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV", J Virol, 78, pp.6024~6032 (2004)
33. Vremec D, "CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen", J Immunol, 164, pp.2978~2986 (2000)
34. Merad M, "The dendritic cell lineage : ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting", Annu Rev Immunol, 31, pp.563~604 (2013)
35. Cannon MJ, "Clearance of persistent respiratory syncytial virus infections in immunodeficient mice following transfer of primed T cells", Immunology, 62, pp.133~138 (1987)
36. Cannon MJ, "Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus", J Exp Med, 168, pp.1163~1168 (1988)
37. Ostler T, "Virus clearance and immunopathology by CD8(+)T cells during infection with respiratory syncytial virus are mediated by IFN-gamma", Eur J Immunol, 32, pp.2117~2123 (2002)
38. Retamal-Díaz A, "Contribution of resident memory CD8+T cells to protective immunity against respiratory syncytial virus and their impact on vaccine design", Pathogens, 8, pp.147~ (2019)
39. Olson MR, "CD8 T cells inhibit respiratory syncytial virus(RSV)vaccine-enhanced disease", J Immunol, 179, pp.5415~5424 (2007)
40. Bhat R, "Double-edged role of natural killer cells during RSV infection", Int Rev Immunol, 39, pp.233~244 (2020)
41. Vankayalapati R, "NK cells regulate CD8+ T cell effector function in response to an intracellular pathogen", J Immunol, 172, pp.130~137 (2004)
42. Crouse J, "NK cells regulating T cell responses : mechanisms and outcome", Trends Immunol, 36, pp.49~58 (2015)
43. Hussell T, "Intracellular IFN-gamma expression in natural killer cells precedes lung CD8+ T cell recruitment during respiratory syncytial virus infection", J Gen Virol, 79, pp.2593~2601 (1998)
44. Li F, "Natural killer cells are involved in acute lung immune injury caused by respiratory syncytial virus infection", J Virol, 86, pp.2251~2258 (2012)
45. Schmidt ME, "Memory CD8 T cells mediate severe immunopathology following respiratory syncytial virus infection", PLoS Pathog, 14, pp.e1006810~ (2018)

관련 논문AI추천